323990 — Vaxcell Bio Therapeutics Share Price
0.000.00%
Last trade - 00:00- KR₩383bn
- KR₩334bn
- KR₩14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.59 | ||
| Price to Tang. Book | 4.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 27,928.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.69% | ||
| Return on Equity | -19.24% | ||
| Operating Margin | -83848.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | n/a | n/a | n/a | n/a | 13.72 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaxcell-Bio Therapeutics is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 18th, 2010
- Public Since
- September 22nd, 2020
- No. of Shareholders
- 89,674
- No. of Employees
- 57
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 22,964,545
- Address
- Biomaterials Incubation Center, HWASUN, 58141
- Web
- http://www.vaxcell-bio.com/
- Phone
- +82 613730046
- Auditors
- Shinhan Accounting Corporation
Upcoming Events for 323990
Q2 2024 Vaxcell Bio Therapeutics Earnings Release
Similar to 323990
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
ADM Korea
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
What is the Vaxcell Bio Therapeutics share price?
As of Today at 19:23 UTC, shares in Vaxcell Bio Therapeutics are trading at KR₩16,690. This share price information is delayed by 15 minutes.
How has the Vaxcell Bio Therapeutics share price performed this year?
Shares in Vaxcell Bio Therapeutics last closed at KR₩16,690 and the price had moved by -59.65% over the past 365 days. In terms of relative price strength the Vaxcell Bio Therapeutics share price has underperformed the FTSE Developed Asia Pacific Index by -57.89% over the past year.
What are the analyst and broker recommendations for Vaxcell Bio Therapeutics?
There is no consensus recommendation for this security.
What is the Vaxcell Bio Therapeutics dividend yield?
Vaxcell Bio Therapeutics does not currently pay a dividend.
Does Vaxcell Bio Therapeutics pay a dividend?
Vaxcell Bio Therapeutics does not currently pay a dividend.
When does Vaxcell Bio Therapeutics next pay dividends?
Vaxcell Bio Therapeutics does not currently pay a dividend.
How do I buy Vaxcell Bio Therapeutics shares?
To buy shares in Vaxcell Bio Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaxcell Bio Therapeutics?
As of the previous close price of KR₩16,690, shares in Vaxcell Bio Therapeutics had a market capitalisation of KR₩383bn.
Where are Vaxcell Bio Therapeutics shares listed?
Here are the trading details for Vaxcell Bio Therapeutics:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 323990
What kind of share is Vaxcell Bio Therapeutics?
Based on an overall assessment of its quality, value and momentum Vaxcell Bio Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaxcell Bio Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Vaxcell Bio Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxcell Bio Therapeutics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -26.25%.
As of the last closing price of KR₩16,690, shares in Vaxcell Bio Therapeutics were trading -24.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaxcell Bio Therapeutics PE Ratio?
The Vaxcell Bio Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩16,690.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaxcell Bio Therapeutics?
We do not have data on Vaxcell Bio Therapeutics' directors